These results suggest that METTL14 enhances the anti-proliferative effects of sorafenib by modulating the PI3K/Akt pathway, while FTH1 and PI3K inhibition counteract this modulation, impacting cell proliferation and survival dynamics in cancer cells. This evidence concerns the gene METTL14 and cancer.